Ikonisys gets US nod to market automated prenatal diagnostic:
This article was originally published in Clinica
The US FDA has given Ikonisys clearance to market its automated scanning microscope-based test for prenatal genetic diagnosis. The Ikoniscope fastFISH amnio test system is an in vitro diagnostic for aiding in the detection of the most common chromosomal aneuploidies for chromosomes 21 (Down's syndrome), 18 (Edward syndrome), 13 (Patau syndrome) and for numerical aberrations for sex chromosomes X and Y. The test can provide a result within 24-36 hours. Commenting on the US approval, Ikonisys chairman and CEO Petros Tsipouras said: "It will give us the opportunity to market our first product - to the largest market in the world."
You may also be interested in...
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.
Market Intel: Why Telehealth, Digital Therapies Will Provide Mental Health Support Beyond COVID-19 Crisis
In this second part of a two-part series focusing on mental health tech, Medtech Insight highlights behavioral digital health companies that have attracted investors’ attention. Part one focused on transcranial magnetic stimulation.